3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
zanidatamab
1
trametinib
1
pembrolizumab
1
larotrectinib
1
durvalumab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Biliary Tract Neoplasms
×
durvalumab
×
Clear all
NCT03875235
2026-05-26
TOPAZ-1
AstraZeneca
Phase 3
Active not recruiting
810 enrolled
24 charts
1 FDA